Clinic
Ascension Seton
Ascension Seton was paid $511K by Medicaid between Dec 2020 and Nov 2024, across 38 billing codes. Its largest line is 99284, emergency room visit (serious) — 59% of everything it billed.
33Billing provider infoASCENSION SETON
AUSTIN, TX 78701
AUSTIN, TX 78701
33aNPI1093810327assigned 09/13/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$511K
24GClaims14,903
24DCodes billed38
24AFirst – last monthDec 2020 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#144 of 320
Median peer was paid$205K
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 26 | $264.25 | |
| 2021 | 4,760 | $184K | |
| 2022 | 5,288 | $237K | |
| 2023 | 3,432 | $62K | |
| 2024incomplete | 1,397 | $27K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 59% | 1,517 | 1,403 | $301K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 1,199 | 1,101 | $122K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.1% | 718 | 639 | $26K |
| 80053 | Comprehensive metabolic panel | 2.6% | 2,515 | 2,117 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 3,578 | 2,884 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 917 | 853 | $9K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 449 | 429 | $5K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 41 | 41 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 495 | 486 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 672 | 624 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 70 | 69 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 208 | 193 | $1K |
26 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 328 | $979.44 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 34 | $703.53 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 314 | $562.29 |
| 84484 | <1% | 339 | $406.72 | |
| 81001 | <1% | 483 | $347.25 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $314.58 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 51 | $225.00 |
| 82803 | <1% | 81 | $214.55 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $164.02 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 63 | $103.32 |
| 83880 | <1% | 13 | $95.64 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 168 | $74.45 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28 | $48.78 |
| 83605 | <1% | 51 | $46.96 | |
| 83690 | <1% | 45 | $45.70 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 85 | $45.39 |
| 81025 | <1% | 13 | $38.15 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 90 | $20.69 |
| 85610 | <1% | 54 | $18.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13 | $14.11 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 47 | $0.02 |
| 82330 | 0% | 17 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 63 | $0.00 |
| A9270 | Non-covered item or service | 0% | 72 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 17 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLLY, JULIE (REGIONAL DIR NET REV & REIMB)
Parent organizationASCENSION SETON
| Provider | Location | Paid |
|---|---|---|
| Ascension Seton | Kyle, TX | $3.00M |
| Cedar Park Health System LLC | Cedar Park, TX | $771K |
| Ascension Seton | Elgin, TX | $94K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.